SynthesisFrontiers in microbiology2025
A bibliometric study of global trends in diabetic nephropathy and intestinal flora research.
Synthesis in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Potential Causal Relationship Between Hypertension and Type 2 Diabetic Nephropathy: Integrating Mendelian Randomization Evidence with Global Burden of Disease 2021 Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Integrative multi-omics analysis prioritizes compartment-specific candidate targets of gut microbiota metabolites in diabetic kidney disease.Frontiers in immunology · 2026Article
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- Comprehensive Mendelian randomization analysis of inflammatory networks in diabetic nephropathy and pituitary adenoma: unveiling complex causal relationships.Discover oncology · 2025Article
- Gut microbiota-derived short-chain fatty acids mediate the antifibrotic effects of traditional Chinese medicine in diabetic nephropathy.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy is chronic kidney damage caused by diabetes and is one of the most common microvascular complications of diabetes. In diabetic patients, prolonged hyperglycemia leads to progressive damage to kidney structure and function. With the increasing incidence of diabetes, the number of patients with Diabetic Nephropathy is also increasing year by year. At present, there is no drug to cure Diabetic Nephropathy. More and more evidence shows that the development of Diabetic Nephropathy is inseparable from the intestinal axis, and the disorder of intestinal flora is related to the progress of diabetes. Maybe we can explore the pathogenesis of Diabetic Nephropathy from the intestinal flora and find new methods to treat Diabetic Nephropathy. Methods: This article uses CiteSpace VOSviewer and Bibliometrix statistical software explore research hotspots and trends of intestinal flora and Diabetic Nephropathy. The Web of Science Core Collection (WoSCC) was searched for literature from database establishment to December 4, 2024, and ultimately 238 articles were included for quantitative analysis. Results: The number of publications has been increasing year by year, reaching its peak in 2024. The high-yield institution is Beijing University of Chinese Medicine, and the most productive country is China. Zhang Yi ranks first in the number of publications by the author. After removing the theme word, inflammation appears the most frequently, followed by oxidative stress. The outbreak hotspots are mainly concentrated in uremic toxin, short chain fatty acid, soy milk, aryl hydrocarbon receptor. Conclusion: The exploration of the mechanism of action and therapeutic or adjuvant therapeutic targets of the gut microbiome and its metabolites in DN patients may become a research hotspot in the future direction of DN and gut microbiome. Inflammation, oxidative stress, and the production of urinary toxins in DN patients are the directions for researchers to explore the mechanisms related to DN patients and gut microbiome. Aryl hydrocarbon receptor (AhR), Short-chain fatty acids (SCFAs), Traditional Chinese medicine and soy milk provide researchers with treatment ideas for diabetic nephropathy. Exploring the specific mechanisms and therapeutic effects of DN and gut microbiome requires cohort studies and clinical trials for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.